Navigation Links
The Newly Combined Axcan and Eurand Announce Name Change to Aptalis
Date:5/6/2011

BRIDGEWATER, N.J., May 6, 2011 /PRNewswire/ -- Axcan Intermediate Holdings Inc. announces that it is changing its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand. Aptalis Pharma also has a new corporate logo and website (please visit us at www.aptalispharma.com). 

"Our new name, Aptalis, is intended to capture the essence of two great companies that have transformed into one combined organization. Aptalis brings together the strengths and capabilities of our employees, our robust portfolio and growing pipeline, our innovative platform technologies, and our exceptional manufacturing capabilities to exceed the expectations of customers and patients," said Frank Verwiel, M.D., President and Chief Executive Officer.

Aptalis currently markets several products around the world, including ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, and SALOFALK® and has several compounds in various stages of development targeting unmet medical needs. The pipeline includes another recent acquisition, AEROQUIN® from Mpex Pharmaceuticals, currently in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.

Above all, Aptalis will continue to put patients and their caregivers at the center of everything it does, striving to improve their quality of care thanks to a:

  • Broader range of products in cystic fibrosis and gastrointestinal disorders
  • Robust pipeline, technology platform, and manufacturing capabilities
  • Skilled team of professionals with deep understanding of our customers' needs

Moving forward customers will receive the same great level of service and dedication from Aptalis that they have come to expect from Axcan and Eurand.  

Dr. Verwiel continued, "This is an exciting time for Aptalis on our journey to becoming the reference specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders."

The appropriate filings will be made to officially change the names of the various legal entities in the near future. To learn more about the new identity please visit www.aptalispharma.com, or call our customer service center at 1-877-275-1925.

About Aptalis

Aptalis Pharma Inc., is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, and SALOFALK®.  Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.aptalispharma.com.

Forward-Looking Statement

This news release contains forward-looking statements for Aptalis Pharma Inc. and its affiliates ("Company") within the meaning of the U.S. federal securities laws. Statements other than statements of historical facts including, without limitation, statements regarding our business strategy and objectives of management for future operations, are forward-looking statements. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that assumptions regarding future events may ultimately prove to be incorrect and undue reliance should not be placed on these forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except as required by law. Please refer to the Company's U.S. SEC filings for further discussion of the Company's business, financial results and risks

Contact
Steve Gannon
Senior Vice President and Chief Financial Officer
(450) 467-2600
sgannon@aptalispharma.com


'/>"/>
SOURCE Aptalis Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Pharm Holdings Group Obtains Business License for its Newly Established Joint-Venture in Jinan City
2. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
3. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
4. Breakaway From Cancer® Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients
5. Zimmer Showcases Newly Acquired Line of Surgical Power Tools at 2011 AAOS Annual Meeting
6. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
7. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
8. Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy
9. Capital BlueCross Newly Designed Health Care Reform Web Portal Features New Videos, Interactive Tool
10. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
11. First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of Home ... and the Home Health and Hospice ICD-10 Transition Workgroup are working closely with ... guidance and clarifications, to address concerns over the use of 'A' as the ...
Breaking Medicine News(10 mins):